Is 'good enough' bulk secondary packaging costing your operation?
Caitlin Richardson
In the biopharma sector, the requirement to preserve the integrity of solid input materials, such as high-purity bioprocess chemicals, bioexcipients and dry culture media, is non-negotiable. While manufacturing occurs in strictly controlled environments, a significant portion of a product's lifecycle is spent in storage, handling and transport. Once these materials leave the production floor, secondary bulk packaging becomes the primary system protecting the product’s condition.
For biopharma supply chain and operations leads, managing this phase is often a balancing act between efficiency and risk. However, viewing biopharma packaging as a simple commodity rather than a strategic asset can lead to hidden costs that disrupt production schedules and impact patient access.
The high cost of reactive logistics
Biopharma supply chains for solid materials are becoming increasingly fragmented, involving specialized partners and multiple physical transfers. Each handoff increases the vulnerability of the material to environmental factors and mishandling. In fact, in a recent survey, nearly 44% of industry respondents had experienced damage due to improper handling or temperature control in the last two years [1].
When bulk packaging for pharma fails, the consequences are felt immediately across the operation:
- Increased scrutiny: Failures often result in rejected shipments, complex investigations and challenges to a supplier’s ongoing qualification status.
- Production delays: Compromised materials, such as moisture-sensitive powders that have caked or agglomerated, may require additional sub-operations to break down before use, if they can be used at all.
- Financial impact: For blockbuster products, production disruptions can cost up to $8 million per day [2].
Shifting from reaction to prepared control
To maintain predictable performance, biopharma suppliers are shifting from a reactive ‘fix-it-after-failure’ approach to one of ‘prepared control’. This discipline focuses on demonstrating risk management before a deviation occurs.
By selecting packaging solutions for bioprocess ingredients that are engineered for real-world stress, operations leads can reduce "hidden" logistical friction.
1. Eliminating contamination pathways
Contamination risk beyond production is primarily introduced through physical handling. Standard fiber-based drums can shed particulates or support microbial growth in humid warehouses. Transitioning to fully plastic drums, pails and jars can help to minimize these sources of foreign material. Smooth, high-density polyethylene (HDPE) surfaces support easier wipe-down procedures during warehouse-to-cleanroom transitions, reducing the bioburden carried into ISO-controlled environments.
2. Engineering moisture protection
For granular materials, moisture tolerance is effectively zero. Reliance on deformable metal clamping rings can lead to inconsistent sealing. In contrast, screw-top closures with integrated gaskets provide repeatable barrier integrity and controlled resistance to moisture vapor transmission. This ensures material readiness at the point of use without the need for corrective testing.
3. Resilience against mechanical stress
Transport introduces vibrations, stacking loads and pressure changes. Secondary packaging must withstand these stresses to avoid visible deformation, which is frequently interpreted by quality teams as a loss of integrity, triggering an automatic rejection on receipt. Utilizing UN-certified packaging provides documented evidence of mechanical robustness under defined load and drop scenarios.
Enhancing operational efficiency
The right packaging does more than just protect; it optimizes. Standardizing on high-performance secondary packaging supports:
- Consistent lead times: Reducing the risk of rejected shipments ensures a predictable flow of materials.
- Audit confidence: Documented performance data and GMP-manufactured consistency simplify the qualification process and technical agreements.
- Safety and handling: Features like easy-to-open screw tops and nestable designs reduce the physical strain on operations personnel and optimize warehouse space.
Build preparedness into your strategy
Preparedness is an ongoing discipline that starts with choosing the right partner. By qualifying packaging systems designed for the rigors of the global biopharma ecosystem, suppliers can ensure smoother audits, fewer investigations and greater continuity.
Ready to reduce the hidden costs in your supply chain? Download our full whitepaper to learn how to build a more resilient secondary packaging strategy.
References
- Tive and BioPharma Dive. (2025, January 21). How pharma supply chain leaders are mitigating rising security risks with visibility technology [Industry survey report]. Tive. https://www.tive.com/ed-research-papers/read-how-pharma-supply-chain-leaders-are-mitigating-rising-security-risks-with-visibility-technology
- Roth, C. (2019, May 9). The real cost of clinical trials. Praxis Communications. https://www.gopraxis.com/news/the-real-cost-of-clinical-trials/
